Evolving panorama of treatment for metastatic pancreas adenocarcinoma

Journal of Clinical Oncology

Volumn 31, Issue 13, 2013, Pages 1621-1623

  O'Reilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CO 101; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GEMCITABINE ELAIDATE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG METABOLISM; EDITORIAL; HUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; FEMALE; MALE; NOTE; PANCREAS TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; PANCREATIC NEOPLASMS;

EID: 84884562140     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.7660     Document Type: Editorial

References (26)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806, 2008
3. Tuveson DA, Neoptolemos JP: Understanding metastasis in pancreatic cancer: A call for new clinical approaches. Cell 148:21-23, 2012
4. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
5. Von Hoff DD, Ervin TJ, Arena FP, et al: Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol 30, 2012 (LBA148)
6. Ueno H, Ioka T, Ikeda M, et al: Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 31:1640-1648, 2013
7. Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: The FLAGS trial. J Clin Oncol 28:1547-1553, 2010
8. Okusaka T, Funakoshi A, Furuse J, et al: A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615-621, 2008
9. Kawashima H, Itoh A, Ohno E, et al: Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Cancer Chemother Pharmacol 68:677-683, 2011
10. Ozaka M, Matsumura Y, Ishii H, et al: Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Res Organization PC-01 study). Cancer Chemother Pharmacol 69:1197-1204, 2012
11. Ueseka K, Fukitami A, Boku N, et al: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 30:145, 2012
12. Yong WP, Innocenti F, Ratain MJ: The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 62:35-46, 2006
13. Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275, 2002
14. Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513-5518, 2009
15. Boeck S, Hoehler T, Seipelt G, et al: Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): Final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 19:340-347, 2008
16. Riess H, Helm A, Niedergethmann M, et al: A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 23:1092s, 2005 (suppl; abstr LBA4009)
17. Farrell JJ, Elsaleh H, Garcia M, et al: Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136:187-195, 2009
18. Mori R, Ishikawa T, Ichikawa Y, et al: Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 17:1201-1205, 2007
19. Von Hoff DD, Ramanathan RK, Borad MJ, et al: Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: A phase I/II trial. J Clin Oncol 29:4548-4554, 2011
20. Sangar V, Ricigliano M, O'Reilly EM, et al: Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance. J Clin Oncol 30:142, 2012
21. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
22. Olive KP, Jacobetz MA, Davidson CJ, et al: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324:1457-1461, 2009
23. Feldmann G, Fendrich V, McGovern K, et al: An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 7:2725-2735, 2008
24. Hidalgo M, Maitra A: The hedgehog pathway and pancreatic cancer. N Engl J Med 361:2094-2096, 2009
25. Feldmann G, Habbe N, Dhara S, et al: Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 57:1420-1430, 2008
26. Provenzano PP, Cuevas C, Chang AE, et al: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21:418-429, 2012